CA2554085A1 - Composition pharmaceutique a usage local contenant un agent cholinergique ou un inhibiteur calcique - Google Patents

Composition pharmaceutique a usage local contenant un agent cholinergique ou un inhibiteur calcique Download PDF

Info

Publication number: CA2554085A1
Authority: CA; Canada
Prior art keywords: anal; composition; haemorrhoids; nifedipine; treatment
Prior art date: 1997-12-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002554085A

Other languages

English (en)

Inventor

Michael Albert Kamm

Robin Kenneth Stewart Phillips

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SLA Pharma AG

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-23

Filing date

1998-02-23

Publication date

1998-08-27

1997-12-23 Priority claimed from GBGB9727238.9A external-priority patent/GB9727238D0/en

1998-02-23 Application filed by Individual filed Critical Individual

1998-02-23 Priority claimed from CA002281755A external-priority patent/CA2281755C/fr

1998-08-27 Publication of CA2554085A1 publication Critical patent/CA2554085A1/fr

Status Abandoned legal-status Critical Current

Links

239000003795 chemical substances by application Substances 0.000 title abstract description 9
229940127291 Calcium channel antagonist Drugs 0.000 title abstract description 6
239000000480 calcium channel blocker Substances 0.000 title abstract description 6
230000001713 cholinergic effect Effects 0.000 title abstract description 5
239000012049 topical pharmaceutical composition Substances 0.000 title description 2
208000016583 Anus disease Diseases 0.000 claims abstract description 28
208000014617 hemorrhoid Diseases 0.000 claims abstract description 26
238000011282 treatment Methods 0.000 claims abstract description 19
206010002153 Anal fissure Diseases 0.000 claims abstract description 18
208000009531 Fissure in Ano Diseases 0.000 claims abstract description 16
239000000203 mixture Substances 0.000 claims description 25
150000003839 salts Chemical class 0.000 claims description 15
229960001597 nifedipine Drugs 0.000 claims description 14
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 14
210000002255 anal canal Anatomy 0.000 claims description 13
239000003814 drug Substances 0.000 claims description 13
230000000699 topical effect Effects 0.000 claims description 10
230000003444 anaesthetic effect Effects 0.000 claims description 8
239000006071 cream Substances 0.000 claims description 8
239000000499 gel Substances 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
210000005070 sphincter Anatomy 0.000 claims description 5
208000005392 Spasm Diseases 0.000 claims description 4
239000002674 ointment Substances 0.000 claims description 4
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 3
210000005072 internal anal sphincter Anatomy 0.000 claims description 3
229960004194 lidocaine Drugs 0.000 claims description 3
238000011321 prophylaxis Methods 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
210000000436 anus Anatomy 0.000 abstract description 8
229960004166 diltiazem Drugs 0.000 abstract description 6
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 abstract description 6
230000000284 resting effect Effects 0.000 abstract description 6
NZUPCNDJBJXXRF-UHFFFAOYSA-O bethanechol Chemical compound C[N+](C)(C)CC(C)OC(N)=O NZUPCNDJBJXXRF-UHFFFAOYSA-O 0.000 abstract description 5
229960000910 bethanechol Drugs 0.000 abstract description 5
239000013543 active substance Substances 0.000 abstract description 2
230000035876 healing Effects 0.000 abstract 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
238000001356 surgical procedure Methods 0.000 description 9
229940079593 drug Drugs 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
229920002125 Sokalan® Polymers 0.000 description 6
239000002585 base Substances 0.000 description 6
229960001760 dimethyl sulfoxide Drugs 0.000 description 6
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
229960001631 carbomer Drugs 0.000 description 5
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 3
230000037213 diet Effects 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000012148 non-surgical treatment Methods 0.000 description 3
239000012188 paraffin wax Substances 0.000 description 3
230000002335 preservative effect Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
235000014150 Myroxylon pereirae Nutrition 0.000 description 2
244000302151 Myroxylon pereirae Species 0.000 description 2
208000012287 Prolapse Diseases 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000001804 emulsifying effect Effects 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
229960002056 indoramin Drugs 0.000 description 2
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 2
238000000034 method Methods 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000001157 myroxylon pereirae klotzsch resin Substances 0.000 description 2
239000002840 nitric oxide donor Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
230000035515 penetration Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
210000000664 rectum Anatomy 0.000 description 2
GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
239000011787 zinc oxide Substances 0.000 description 2
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
XFZJGFIKQCCLGK-UHFFFAOYSA-M 1,1-dimethyl-4-phenylpiperazinium iodide Chemical compound [I-].C1C[N+](C)(C)CCN1C1=CC=CC=C1 XFZJGFIKQCCLGK-UHFFFAOYSA-M 0.000 description 1
IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
206010000060 Abdominal distension Diseases 0.000 description 1
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
102400000967 Bradykinin Human genes 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
108010010737 Ceruletide Proteins 0.000 description 1
206010010539 Congenital megacolon Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
241000792859 Enema Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
102000051325 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
241000208690 Hamamelis Species 0.000 description 1
229920001499 Heparinoid Polymers 0.000 description 1
206010019909 Hernia Diseases 0.000 description 1
208000004592 Hirschsprung disease Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010036772 Proctalgia Diseases 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
208000003734 Supraventricular Tachycardia Diseases 0.000 description 1
206010042674 Swelling Diseases 0.000 description 1
108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
206010046555 Urinary retention Diseases 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000000159 acid neutralizing agent Substances 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
229960001456 adenosine triphosphate Drugs 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 1
108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229940124326 anaesthetic agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
-1 at 0.1 to 5% w/w) Chemical compound 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
150000001621 bismuth Chemical class 0.000 description 1
229910000416 bismuth oxide Inorganic materials 0.000 description 1
229940036359 bismuth oxide Drugs 0.000 description 1
JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 description 1
229960000199 bismuth subgallate Drugs 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000008142 bulk forming laxative Substances 0.000 description 1
229930190815 caerulein Natural products 0.000 description 1
CNYFJCCVJNARLE-UHFFFAOYSA-L calcium;2-sulfanylacetic acid;2-sulfidoacetate Chemical compound [Ca+2].[O-]C(=O)CS.[O-]C(=O)CS CNYFJCCVJNARLE-UHFFFAOYSA-L 0.000 description 1
229940031663 carbomer-974p Drugs 0.000 description 1
206010061592 cardiac fibrillation Diseases 0.000 description 1
YRALAIOMGQZKOW-HYAOXDFASA-N ceruletide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-HYAOXDFASA-N 0.000 description 1
229960001706 ceruletide Drugs 0.000 description 1
229950009789 cetomacrogol 1000 Drugs 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
230000013872 defecation Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
TYIXMATWDRGMPF-UHFFFAOYSA-N dibismuth;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Bi+3].[Bi+3] TYIXMATWDRGMPF-UHFFFAOYSA-N 0.000 description 1
229960005316 diltiazem hydrochloride Drugs 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
229960002986 dinoprostone Drugs 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000008387 emulsifying waxe Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
230000002600 fibrillogenic effect Effects 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
239000002554 heparinoid Substances 0.000 description 1
229940025770 heparinoids Drugs 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
229960001317 isoprenaline Drugs 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000008274 jelly Substances 0.000 description 1
229960003639 laurocapram Drugs 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
239000006210 lotion Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
229960001999 phentolamine Drugs 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000004040 pyrrolidinones Chemical class 0.000 description 1
239000003229 sclerosing agent Substances 0.000 description 1
230000037067 skin hydration Effects 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
238000007464 sphincterotomy Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
YRALAIOMGQZKOW-UHFFFAOYSA-N sulfated caerulein Natural products C=1C=CC=CC=1CC(C(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(C(C)O)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C1NC(=O)CC1)CC1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
206010047302 ventricular tachycardia Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229960001296 zinc oxide Drugs 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002554085A 1997-12-23 1998-02-23 Composition pharmaceutique a usage local contenant un agent cholinergique ou un inhibiteur calcique Abandoned CA2554085A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9727238.9		1997-12-23
GBGB9727238.9A GB9727238D0 (en)	1997-12-23	1997-12-23	Pharmaceutical composition
CA002281755A CA2281755C (fr)	1997-02-24	1998-02-23	Composition pharmaceutique a usage local contenant un agent cholinergique ou un inhibiteur calcique

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002281755A Division CA2281755C (fr)	1997-02-24	1998-02-23	Composition pharmaceutique a usage local contenant un agent cholinergique ou un inhibiteur calcique

Publications (1)

Publication Number	Publication Date
CA2554085A1 true CA2554085A1 (fr)	1998-08-27

Family

ID=36998250

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002554085A Abandoned CA2554085A1 (fr)	1997-12-23	1998-02-23	Composition pharmaceutique a usage local contenant un agent cholinergique ou un inhibiteur calcique

Country Status (1)

Country	Link
CA (1)	CA2554085A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2958570A4 (fr) *	2013-02-19	2016-07-20	David Jonathan Hochman	Composition thérapeutique pour le traitement de troubles périanaux

1998
- 1998-02-23 CA CA002554085A patent/CA2554085A1/fr not_active Abandoned

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2958570A4 (fr) *	2013-02-19	2016-07-20	David Jonathan Hochman	Composition thérapeutique pour le traitement de troubles périanaux

Publication	Publication Date	Title
CA2281755C (fr)	2006-11-07	Composition pharmaceutique a usage local contenant un agent cholinergique ou un inhibiteur calcique
US5504117A (en)	1996-04-02	Pharmacologic preparation for the treatment of anal disorders
US20070003627A1 (en)	2007-01-04	Hemorrhoidal compositions and method of use
US4708873A (en)	1987-11-24	Method of chemically debriding uncerated necrotic tissue
US8048875B1 (en)	2011-11-01	Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
AU2003203991B2 (en)	2005-10-27	Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
AU758944B2 (en)	2003-04-03	Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
US20220249512A1 (en)	2022-08-11	Topical pharmaceutical compositions comprising diltiazem
CA2554085A1 (fr)	1998-08-27	Composition pharmaceutique a usage local contenant un agent cholinergique ou un inhibiteur calcique
JP2005029529A (ja)	2005-02-03	痔疾治療薬
JP2023506720A (ja)	2023-02-20	肛門疾患を治療するための薬理学的組成物（変形）
JPWO2016121147A1 (ja)	2017-11-02	注腸剤
JP2000119186A (ja)	2000-04-25	スクラルファート含有局所投与用医薬組成物
US20150374644A1 (en)	2015-12-31	Therapeutic Composition for the Treatment of Perianal Disorders
JP5777156B2 (ja)	2015-09-09	慢性痒疹治療用外用剤
US4713377A (en)	1987-12-15	Method of ameliorating obstructions of the bowel
US20250186376A1 (en)	2025-06-12	Topical composition for treating injuries or cutaneous inflammatory states or proctological pathologies
US20120046318A1 (en)	2012-02-23	Methods and compositions for treating internal and external hemorrhoids

Legal Events

Date	Code	Title	Description
2006-07-31	EEER	Examination request
2013-03-04	FZDE	Dead	Effective date: 20130107

CA2554085A1 - Composition pharmaceutique a usage local contenant un agent cholinergique ou un inhibiteur calcique - Google Patents

Info

Links

Landscapes

Applications Claiming Priority (3)

Related Parent Applications (1)

Publications (1)

Family

ID=36998250

Family Applications (1)

Country Status (1)

Cited By (1)

Cited By (1)

Similar Documents

Legal Events